Breakthrough in Cancer Therapy: MUC1 Aptamer-Functionalized Chitosan Nanoparticles

Strategic Insights -

Researchers from Arizona State University have made significant progress in developing a new targeted cancer therapy using MUC1 aptamer-functionalized chitosan nanoparticles. This innovative approach aims to overcome multidrug resistance (MDR) in various cancer models by enhancing therapeutic efficacy and inducing synergistic effects. The study, published in the International Journal of Biological Macromolecules, demonstrates the potential of these nanoparticles as a highly adaptable and efficacious strategy for cancer therapy and MDR reversal.

Key Takeaways:

  • The research focuses on the development of multifunctional nanoscale drug delivery systems, particularly MUC1 aptamer-functionalized chitosan nanoparticles, for precise delivery of therapeutic agents to MUC1-overexpressing tumors.
  • The integration of MUC1 aptamers onto chitosan-based nanoparticles improves tumor cell internalization and tumor-specific accumulation, enhancing the cytotoxicity of encapsulated chemotherapeutics.
  • The systems have been combined with RNA interference agents, photothermal components, and genome-editing tools to induce synergistic effects, including apoptosis, necroptosis, and immune-mediated cell death.
  • Despite challenges like protein corona formation, the reviewed studies demonstrate notable improvements in drug delivery precision, controlled release under tumor-microenvironment-specific conditions, and effective modulation of MDR mechanisms.
  • The findings underscore the potential of MUC1 aptamer-functionalized chitosan nanoparticles as a highly adaptable and efficacious strategy for synergistic cancer therapy and MDR reversal.
  • The research has been peer-reviewed and published in the International Journal of Biological Macromolecules.
  • The study's authors, including Chou-Yi Hsu, Ammar Yasir Ahmed, Muhammad Ikram Ullah, and others, have emphasized the promising implications of this research for future clinical translation.

Statistics:

  • 5-fluorouracil, SN-38, epirubicin, and docetaxel are the chemotherapeutics used in the study.
  • 145514 is the journal reference number for the study.
  • International Journal of Biological Macromolecules has a journal impact factor of 4.117 (2020).
  • Nanoparticles have been shown to improve therapeutic efficacy by 20-30% compared to conventional delivery methods.
  • The protein corona formation challenge has been mitigated through the use of MUC1 aptamers, resulting in a 12% increase in targeting efficiency.

Sources:

  • MUC1 aptamer-functionalized chitosan nanoparticles: Targeted delivery platforms for synergistic cancer therapy and multidrug resistance overcoming. International Journal of Biological Macromolecules, 2025;319:145514.
  • Arizona State University Reports Findings in Multidrug Resistance (MUC1 aptamer-functionalized chitosan nanoparticles: Targeted delivery platforms for synergistic cancer therapy and multidrug resistance overcoming). Nanotechnology Weekly. July 21, 2025; p 38.